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Effectiveness is a concept central to Health Technology Assess-
ment (HTA). Effectiveness is the measure of whether and how
well an intervention works to mitigate disease and to enhance
and extend human life in normal practice. Effectiveness is “the
what” or the noun of HTA. In the current issue, Ridyard and
Hughes have conducted an evaluation of how well researchers
have studied costs within a selection of 100 primary research
articles published in the British journal—Health Technology
Assessment [1]. Their evaluation concerns “the how” of eco-
nomic evaluation alongside clinical trials. They evaluated the
methods and means of collecting, describing, and analyzing eco-
nomic information. As a descriptive article concerning the
methods of economic evaluations alongside clinical trials, this
work will be useful for health outcomes researchers seeking to
optimize the collection of economic information. Clearly, good
research techniques serve to strengthen economic ﬁndings and
make them more credible. But a potentially more important
question, not addressed by Hughes, is whether a trial should
lead to a companion economic evaluation.
The methods and means of effectiveness research are pivotal
considerations in HTA. Effectiveness includes an assessment of
efﬁcacy, but it also considers whether a clinical intervention
works as well in real world settings as it does in controlled trials.
Both evaluative settings are needed for robust and credible esti-
mates of beneﬁt and risk in actual practice. Methodological
concerns are central to effectiveness estimates. Regulatory
authorities, including the Food and Drug Administration and the
International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human
Use, have issued the E10 Guidance (Choice of Control Group in
Clinical Trials) [2]. The guidance describes the types and appro-
priateness of trial designs and provides a wealth of methodologi-
cal considerations. Furthermore, the CONSORT initiative
(http://www.consort-statement.org) has issued guidance to
enable readers and researchers to critically appraise and interpret
clinical trials, and they have updated their recommendations to
include pragmatic trials—or effectiveness considerations [3].
Why are these references important to economic evaluations of
clinical trials and HTA? If one thinks of effectiveness as a noun
and economic evaluation as an adjective, then they should align
to optimize clarity and perhaps appropriateness. A proper esti-
mate of effectiveness is the foundation for sound HTA decisions.
In 2008, a position paper was issued, entitled: National Insti-
tute for Health and Clinical Excellence (NICE): How does it
work and what are the implications for the United States? The
article was authored by Sorenson, Drummond, Kanavos, and
McGuire and is available through Michael Drummond [4]. This
article has a section on “assessment processes” and the evidence
normally preferred and accepted by NICE. In the “hierarchy of
preferred study designs,” as a reliable basis for relative
therapeutic effects, the lowest level is “expert opinion,” level 3 is
“observational studies without control,” level 2 is “controlled
observational studies,” and level 1 is “randomized controlled
trials” (RCTs). “The RCT is the ideal method for measuring
treatment effects.” [5] Even though RCTs minimize the potential
for bias and generate the most credible estimates of therapeutic
effect, the D’Agostinos (Junior and Senior) argue that observa-
tional and nonrandomized studies have a role in codifying effec-
tiveness and real-world experiences. They recommend statistical
methods involving matching, stratiﬁcation, and/or covariance
adjustments to minimize bias in effectiveness research. Good
research designs and statistical methods enable generation of the
most credible estimates of effectiveness, which comprehends all
levels of clinical evidence.
The story of drug-eluting stents provides an insightful case of
how randomized and nonrandomized evidence evolves in an
iterative fashion to address clinically important therapeutic ques-
tions of effectiveness [6]. Percutaneous coronary intervention
with drug-eluting or bare metal stents to support optimal blood
ﬂow within the heart has been the subject of signiﬁcant research
over the past three decades. Stenting technology has proved
therapeutically meaningful to reduce disease secondary to a heart
attack, but not without surprises. The stent devices work best
when adjunctive medical therapy is used. It was demonstrated in
observational research that discontinuing antiplatelet medical
therapy too soon after the stent placement was associated with
late stent thrombosis leading to another myocardial infarction
[7,8]. After a host of observational research was conducted to
codify the late effect, JAMA selected two observational (registry)
investigations by Win et al. and Beohar et al. and commissioned
Drs. Harrington and Ohman to explore the contradictory and
somewhat confusing ﬁndings [9,10]. One of their observations
was: “While iterative and exploratory science is not suitable for
development of clinical guidelines, mature science always is.” [6]
They also explored the potential biases in the Win and Beohar
investigations and recommended ways to minimize bias to derive
a more mature estimate of therapeutic effect.
While demand for economic evaluations alongside clinical
trials may be increasing [2,11], serious attention should be exer-
cised concerning whether a trial warrants a companion economic
evaluation. The clinical trial may not have a credible design or
the observational study appropriate adjustments, and therefore,
the associated economic evaluation will be ﬂawed. Investigations
with credible effectiveness estimates, well conceived, conducted,
and characterized along the lines described in the E10,
CONSORT and D’Agostinos publications, will probably deserve
economic evaluations. These characteristics are associated with
the clinical investigations, not with the economic evaluations.
The economic ﬁndings are informative or hypothesis-generating.
The clinical investigations provide the foundation for effective-
ness estimates of beneﬁt and risk. To my knowledge, no primary
investigation, designed, sized, and powered to explore compara-
tive economic effects, has ever been conducted; that is why I
think of the economic evaluation as an adjective, rather than a
noun.
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